Pancreatic cancer (PC) is a lethal malignancy that lacks specifi c diagnostic markers. The present study explores the diagnostic potential of the most differentially overexpressed secretory mucin MUC5AC alone and in combination with CA19-9 using multi-center training and validation sets.
INTRODUCTION
Pancreatic cancer (PC) is the fourth leading cause of cancerrelated deaths and is predicted to become the second-leading cause of cancer death by 2030 (ref. 1 ). Poor survival for PC patients stems from late diagnosis, asymptomatic early disease stages, high chemotherapy resistance, and rapid metastatic progression ( 2 ) . Th e ability to diagnose PC in asymptomatic patients is expected to allow a greater number of patients to undergo potential curative resection and greatly improve their prognosis.
Identifi cation of eff ective biomarkers for the early diagnosis of PC is an ongoing endeavor. Although several diagnostic biomarkers for PC have been investigated, the majority of these have yielded suboptimal results (3) (4) (5) . CA19-9, the only Food and Drug Administration-approved blood based biomarker for follow-up is useful for disease prognosis, but it has limited utility as an early detection marker due to its variable sensitivity (SN, 60-90%), specifi city (SP, 68-91%), and positive predictive value (PPV, 0.9-2.4%) ( 4, 6, 7 ) . Specifi cally, the diagnostic utility of CA19-9 is sub-optimal mainly due to its elevation under benign conditions such as obstructive jaundice, cirrhosis, cholangitis, and chronic pancreatitis (CP), as well as the inability of 5-10% of the Caucasian population to synthesize this (8) (9) (10) . Furthermore, only 65% of resectable PC cases have elevated levels of CA19-9 in the blood ( 11 ) . In light of the sporadic nature of PC and asymptomatic early disease stages, identifi cation of serum markers that can either complement or perform better than CA19-9 is highly desirable.
Iacobuzio-Donahue et al. ( 12 ) performed comprehensive comparative genomic analyses of normal pancreas or duodenal mucosal tissue, CP, and PC tissue or pancreatic cancer cell lines. MUC5AC was identifi ed as the most diff erentially expressed mucin gene in PC tissue compared with benign pancreatic pathologies. MUC5AC is a member of the mucin family, a heterogeneous group of 21 abundant, high molecular weight O-glycoproteins that can be either secreted or membrane bound ( 2 ) . Due to its secretory nature, the de novo expression, in early pancreatic intraepithelial precursor lesions (PanIN), and the multiplicity of epitopes in its tandem repeat domain, MUC5AC holds promise as a potential diagnostic marker. However, to date, its utility as a serum biomarker for PC remains unexplored.
Th e present study analyzes the utility of MUC5AC as a biomarker for PC at the tissue level and in blood samples from a large patient cohort. Further, this study determines the ability of MUC5AC to diff erentiate between resectable PC patients from healthy controls (HC), benign controls (BC), and CP patients. Th e effi cacy of MUC5AC in diff erentiating resectable (i.e., Stage I-IIB) and unresectable (i.e., Stage III-IV) cases from controls was assessed in a training set and then in independent validation sets.
METHODS

Study population
Th is study was conducted according to guidelines from the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) ( 13 ) . Th e study population included four patient sets from the following three centers: Mayo Clinic Jacksonville, Florida (validation set I), the University of Pittsburgh Medical Center (UPMC) (training set, blinded validation set II, both were independent sample sets), and the University of Nebraska Medical Center (UNMC) (MU5AC response to surgery and chemotherapy). Th e study was approved by the Institutional Review Boards (IRBs) at the Mayo Clinic (IRB number #07-0000099), UPMC (IRB number PRO07030072), and UNMC (IRB number 209-00). Informed written consents were obtained from all patients and controls prior to enrollment in the study. Th ree gastroenterologists, blinded to the results of the assays, determined the fi nal diagnosis of the patients based on standard clinical practices. Patients with benign pathologies such as duodenal ulcers, choledochocele, common bile duct stones, benign stricture, biliary dilation, or abnormal imaging on computed tomography or magnetic resonance imaging scans of the pancreas were categorized as BC. PC staging was determined surgically, based on operative pathology or biopsy of metastatic disease; CP was defi ned based on standard clinical practices. Samples prior to surgery were classifi ed as presurgery. Specimens obtained following resection of the primary tumors with either pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy were considered to be post-surgery samples. Pre-chemotherapy samples included any sample drawn prior to the initiation of systemic chemotherapy. If the patient had ever received chemotherapy for PC, regardless of whether that patient was undergoing chemotherapy at the time of sample collection, then the sample was classifi ed as post-chemotherapy.
For the diagnostic training set, samples collected at UPMC were used; following collection, samples were shipped by overnight mail to the UNMC for processing. Aft er processing, plasma samples were aliquoted and immediately frozen at −70°C. Th e training set was comprised of 43 CP patients, 35 HC, and 30 BC, as well as 70 EPC/resectable patients (Stage I-II) and 63 LPC/unresectable patients (Stage III-IV) who were recruited at UPMC.
For the unblinded validation set I, all blood samples were prospectively collected and processed at the Mayo Clinic ( 14 ) . Patients with epigastric pain/discomfort, no history of pancreatic disease, and normal pancreatic tests (endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, computed tomography, or magnetic resonance imaging) were considered as controls. Th e sample set included 22 controls, 19 patients with CP, and 53 patients with PC; the demographic details for this sample set were published previously ( 14 ) .
Th e independent blinded validation set (set II) was comprised of 321 patients (CP, BC, EPC, and LPC), for which serum samples were collected and stored at UPMC. In the validation set II, all samples from UPMC were collected pretreatment (pre-surgery, pre-chemotherapy). Grade, stage, smoking status, alcohol use, and family history of PC were based on the review of hospital records.
To evaluate changes in the levels of MUC5AC in response to surgery/chemotherapy, this study used a predictive sample set from UNMC obtained prior to or following any treatment (either surgery or chemotherapy). Details on the groups of patients are provided in the supplementary section, and patient demographic data are described in Supplementary Table 1 .
Immunohistochemistry analyses
Immunohistochemistry analyses were performed on commercial tissue microarray (TMA) (Biomax; Cat # PA2081a, B054) containing pancreatic tissues from 101 patients, representing normal pancreatic tissue, cancer adjacent normal pancreas, CP, PANCREAS AND BILIARY TRACT VOLUME 112 | JANUARY 2017
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hyperplasia of ducts, islet cell tumors, and ductal adenocarcinoma cases. TMA-containing PC-associated PanIN lesions (TMA 375 and 346) were a kind gift from Dr Anirban Maitra at Johns Hopkins University. Immunohistochemistry was performed according to standardized protocol. Briefl y, aft er overnight dewaxing at 58°C, the slides were washed consecutively three times with xylene. Subsequently, the tissue sections were hydrated using a progressively decreasing percentage of alcohol (100, 95, 80, 70, 50, 30, 20, and 0%). Internal peroxidase activity was quenched by incubating slides in 3% hydrogen peroxide diluted in methanol under dark conditions. Antigen retrieval was carried out by heating the slides for 15 min in 10 mM citrate buff er. Once the slides were cooled, the sections were washed with PBS-T (phosphatebuff ered saline with 0.1% Tween 20) and antigens were blocked using horse serum (ImmPRESS Universal antibody kit; Vector Laboratories, Burlingame, CA) for 3 h at room temperature. Th e slides were incubated further with a 1:400 dilutions of anti-MUC5AC antibody (monoclonal antibody CLH2, Abcam, Cambridge, MA). Aft er overnight incubation, the slides were washed four times with PBS-T, followed by incubation with anti-mouse secondary antibody (ImmPRESS Universal antibody kit; Vector Laboratories, Burlingame, CA) for 30 min, and subsequently, the color was developed by adding 3,3ʹ-diaminobenzidine solution (DAB substrate kit; Vector Laboratories, Burlingame, CA). Once reactivity was observed in the form of brown precipitate, the peroxidase reaction was quenched using distilled water, and sections were hematoxylin stained for 1-2 min, followed by dehydration in an increasing percentage of alcohol and consecutively washed three times with xylene. Th e sections were mounted using a Vecta-mount mounting medium (Vector Laboratories). Each tissue spot was evaluated for the H -score, which is the product of the percentage of cells positive in the area for MUC5AC and intensity of staining (on the scale of 0-3). To assess the presence of tumors, percentage of MUC5AC positive cells and intensity of staining (0-3), the slides were analyzed by Pathologist Dr SL Johansson at UNMC.
MUC5AC ELISA
A highly sensitive, novel sandwich ELISA-assay was developed to detect MUC5AC levels in the serum. Briefl y, each well of a 96-well microplate was coated with 100 μ l anti-MUC5AC mouse monoclonal antibody (1-13M1) (a generous gift from Dr. Jacques Bara, INSERM U-482, Paris, France), diluted to the working concentration of 10 μ g/ml in 0.05M carbonate buff er. Plates were sealed and incubated overnight at room temperature. Th e following day, the plates were washed twice with phosphate buff ered saline and 0.1% Tween-20 (PBS-T) using an automated washer. Th e antibody-coated plates were blocked with 250 μ l of 3% fi ltered bovine serum albumin (BSA) for 2.5-3 h at 37 °C, followed by three washes with 0.1% PBS using an automated washer and 100 μ l of sample or standards (one-time prepared lysate of A549 cells expressing high levels of MUC5AC), appropriately diluted in 1% BSA, were added to each well. All samples were run in duplicate. Plates were sealed, incubated overnight at 4 °C, and then washed four times with 0.1% PBS-T. Th en, 100 μ l of biotinylated mouse anti-MUC5AC mAb-1 (45M1) (NeoMarkers, Fremont, CA), diluted in 1% BSA, was added to each well, and plates were incubated for 2 h at 37°C. Plates were again washed with 0.1% PBS-T, and then 100 μ l of Pierce Streptavidin Poly-HRP (Th ermo Scientifi c), diluted to 0.0002 mg/ml in 1% BSA, was added to each well and incubated for 30 minutes at room temperature in the dark. Compared with the modifi ed ELISA assay, in the routine ELISA-assay, normal streptavidin-HRP at 1:200 dilutions in PBS-T in 1% BSA was used. Following washing, 100 μ l of substrate 3,3ʹ,5,5ʹ-Tetramethylbenzidine (TMB) solution was added to each well, and plates were incubated for 20 min at room temperature in the dark. Th en, 50 μ l of 1 M sulfuric acid was added to each well to quench the reaction; the absorbance at 450 and 650 nm was measured using a microplate reader. Th e levels of MUC5AC were quantifi ed as nanogram per ml of total protein in the A549 cell line of lung cancer.
CA19-9 radioimmunoassay
Th e levels of CA19-9 in serum samples were determined by using a solid phase radioimmunoassay (Centocor, Malvern, PA). All samples were analyzed in duplicate according to the manufacturer's recommendations. Th e quantity of CA19-9 antigen was expressed in arbitrary units (U/ml), with one unit activity approxi mately equal to 0.8 ng of purifi ed antigenic protein for CA19-9 in a solid phase radioimmunoassay ( 15 ) .
Statistical analysis
For demographic information, ages were compared using an analysis of variance model. Race and gender distributions were compared between the groups using χ 2 -tests, with Fisher's exact tests utilized for small sample sizes. To ensure that the normality assumption was met, MUC5AC levels were compared between groups using t -tests and analysis of variance models on the log scale. Th e data are presented as median with interquartile range of 25 to 75 (IQR-Q25-Q75). If signifi cant diff erences were found between the overall P -values from the analysis of variance models, then pairwise comparisons were made that adjusted for multiple comparisons using Tukey's method; graphs were plotted using MedCalc (version 9.6.2.0) window application (MedCalc Software, Mariakerke, Belgium). Th e ability of MUC5AC to diff erentiate PC patients from the control groups (BC and CP patients for the initial study) was determined through analysis of the Area Under the Curve (AUC) using Receiver Operating Characteristic curve analysis. Th e diagnostic ability of MUC5AC was compared with that of CA19-9 using AUC in the training set. Cutoff points were determined for each marker using optimal SN and SP. Furthermore, the multivariate models were used to compare the differentiating abilities of MUC5AC alone, and in combination with CA19-9. SAS soft ware version 9.3 (SAS Institute Inc., Cary, NC) was used for all data analysis.
Mixed-eff ects models were used to compare log (MUC5AC) levels between post-and pre-chemotherapy, surgery levels, and diagnosis. Th e model included fi xed eff ects for pre-and postchemotherapy and pre-and postsurgery, and a random eff ect for patients to account for the correlation due to multiple samples
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per patient. Statistical analysis for the diagnostic performance of MUC5AC, at a predetermined cutoff from the training set, was independently investigated in the blinded validation sets.
RESULTS
De novo expression of MUC5AC in early PC lesions
Genome-wide expression analyses identifi ed MUC5AC as the most diff erently overexpressed mucin in PC ( 12 ) . Th e expression of MUC5AC was examined at the tissue level using commercial TMAs Figure 1 ). MUC5AC expression was undetectable in the normal pancreas ( Figure 1a Expression was further assessed in the samples from advanced stages of PC by staining TMAs, courtesy of the UNMC rapid autopsy program (RAP). MUC5AC expression was observed in 76% (22 out of 29 cases) of primary tumors, while normal pancreases from tumor-adjacent areas were negative ( Figure 1d ). Furthermore when metastases were taken into account, the overall incidence of MUC5AC positivity increased to 97% (28 out of 29 cases; Figure 1b ) . Th e percentage positivity values for metastases of the lungs, omentum/diaphragm, lymph nodes, and liver were 85%, 79%, 69%, and 92%, respectively.
Differential expression of circulating MUC5AC in resectable early-stage PC patients
Th is study next evaluated diagnostic signifi cance of circulating MUC5AC using the comprehensive sample set comprising of training, and validation sets from various centers ( Figure 2a , Supplementary Table S1 online). Th e modifi ed MUC5AC ELISA was more sensitive than the conventional ELISA, and was highly reproducible with intra-and inter-plate coeffi cients of variations of 4.7% and 11.4%, respectively ( Supple mentary Figure S1 online). Median circulating MUC5AC levels were signifi cantly elevated in PC patients (124.1 ng/ml, interquartile range (IQR): 39.1-777.8) as compared with HC (4.9 ng/ml, IQR: 0.6-17.4; <0.0001), BC (7.2 ng/ml, IQR: 0.4-26.5; P <0.0001), and CP (8.4 ng/ml, IQR: 1.5-19.2; P <0.0001) patients ( Figure 2b : Table 1 ). Notably, significant diff erences in the median and average MUC5AC levels were maintained when the PC sample set was limited to only cases of early-stage, resectable PC (HC, BC, and CP, P <0.0001) ( Figure 2b , Table 1 ). Th e levels of MUC5AC increased with the stage of PC and in the late stage patients (Stage III and IV), the median level of MUC5AC was found to be higher than Stage IA-IIB patients ( P =0.059; Figure 2c ).
Using Receiver Operating Characteristic curve-based diagnostic analyses ( Figure 2d-f ), MUC5AC eff ectively diff erentiated EPC from all controls ( Figure 2d ). Th e SN/SP for diff erentiating EPC from HC (AUC 0.87; confi dence interval (CI): 0.79-0.95 at ≥20.4 ng/ml); BC (AUC 0.85; CI: 0.76-0.93 at ≥33.6 ng/ml) and CP (AUC 0.84; CI: 0.76-0.92 at ≥20.4 ng/ml); were 83%/80%, 67%/87%, and 83%/77%, respectively ( Supplementary Table 2 ). For LPC, an improved SN/SP was observed for diff erentiating all controls cases with SN/SP of 91%/89% (at ≥35.4 ng/ml), 89%/90% (at ≥41.9 ng/ml), and 91%/84% (at ≥35.4 ng/ml MUC5AC) for HC, BC, and CP, respectively ( Figure 2e , Supplementary Table S2 online). Overall, MUC5AC was found to be a specifi c marker for diff erentiating healthy and benign control groups from PC patients ( Figure 2f ). Based on the Receiver Operating Characteristic curve analysis, a cutoff of 20.4 ng/ml was found to optimally diff erentiate all control groups from EPC (AUC 0.85, SN/ SP of 83%/73%); this cutoff value was further used to assess the diagnostic potential of MUC5AC in validation sets. While assessing the correlation between MUC5AC levels and various clinical characteristics, a marginal association was observed for the smoking status and history of alcohol use (data not shown).
To determine whether MUC5AC levels correlate with tumor progression/disease burden, the eff ects of surgery and chemotherapy on circulating MUC5AC levels were determined. Pre-surgery MUC5AC levels were signifi cantly increased compared with post-surgery levels ( P -value=0.0046) ( Figure 2g ). Further analyses for individual patients indicated a downward trend in MUC5AC 
Analysis of circulating MUC5AC in independent validation sets from different centers
Th e fi rst independent validation set was comprised of patients who presented with epigastric pain/discomfort and underwent upper-gastrointestinal endoscopy at the Mayo Clinic. In this validation set, the expression of MUC5AC was observed to be significantly up-regulated in PC patients as compared with all controls groups ( Supplementary Figure S2B online) . Th e SN/SP of MUC5AC at its defi ned cutoff (20.4 ng/ml) was 75%/73% for differentiating cases of BC from PC, while it was 75%/79% SN/SP for diff erentiating cases of CP from PC. Based on the promising results from the initial validation set, the diagnostic potential of MUC5AC was assessed in a larger, blinded validation set from UPMC, where the samples were diff erent from those used in the training set. In these analyses, MUC5AC diff erentiated PC from BC with a SN/SP of 68%/83% and PC from CP with a SN/SP of 68%/72% (cut-off MUC5AC levels were compared between pre-and post-surgery samples ( n =106) using a mixed-effects model. The model included fi xed effects for preand post-surgery and a random effect for patients to account for the correlation due to multiple samples per patient. Post-surgical levels of MUC5AC were signifi cantly lower than pre-surgical levels. *Stage unknown for some cases. The p-values were determined by the ANOVA t -test. *** P -value ≤0.0001; ** P -value ≤0.001. BC, benign control group; CP, chronic pancreatitis; HC, healthy controls; EPC, early-stage pancreatic cancer (stage 1 and 2); LPC, late-stage pancreatic cancer (stage 3 and 4); PC, pancreatic cancer.
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Kaur et al. online). However, in the EPC group, a marked decrease was observed in the sensitivity (56%, 48%, and 48% for HC, BC and CP respectively), while specifi city remained unchanged ( Figure 3c , Supplementary Table S2 online).
Considering the discriminatory power of both markers, this study next evaluated their performance in combination. First, we investigated the correlation between MUC5AC and CA19-9, both in controls (HC, BC, and CP), and in PC specimens. Th e levels of circulating MUC5AC and CA19-9 antigens did not correlate with one another in the controls (correlation coeffi cient r =−0.081, P =0.5834; Figure 3a ) but exhibited a mild positive correlation in PC patients (correlation coeffi cient r =0.33, P =0.0013; Figure 3b ) .
Th e study then applied a multivariate analysis in the training set to investigate whether combining MUC5AC with CA19-9 could improve the diagnostic accuracy for diff erentiating PC cases from controls (BC and CP). Th e AUC for the combination of MUC5AC with CA19-9 to diff erentiate PC from benign and CP controls was signifi cantly greater (0.91, 0.86-0.95) compared with the AUC for the CA19-9 model alone (0.61, CI: 0.86-0.95; diff erence of 0.3 and P -value <0.0001; Table 3 ). Inclusion of MUC5AC with CA19-9 improved its specifi city (from 43 to 83%) and sensitivity (from 79 to 83%) for diff erentiating PC from all controls ( Table 3 ). value of 20.4 ng/ml; Table 2 ). Th e diagnostic utility of MUC5AC was further evaluated independently in EPC group. In validation set I, MUC5AC diff erentiated EPC from BC with the SN/SP of 68%/73% and CP patients from EPC patients with SN/SP of 68%/79% at 20.4 ng/ml cut-off ( Table 2 ) . Similarly, in validation set II, MUC5AC diff erentiated EPC from BC (AUC=0.74; SN/ S P =65%/83%) and CP (AUC=0.68; SN/SP=65%/72%) controls ( Table 2 ). Interestingly, the SN/SP of MUC5AC in the validation set increased to 72%/92% when the samples ( n =59) had low bilirubin levels (≤1.5) compared with patients ( n =47) having high bilirubin levels (>1.5, SN/SP; 67%/80%) (data not shown).
Improved diagnosis by MUC5AC and CA19-9 combination
Next, this study assessed the diagnostic performance of MUC5AC in combination with CA19-9, the current gold-standard PC biomarker. Similar to MUC5AC, CA19-9 levels were signifi cantly elevated in cases of both EPC and LPC compared with all control groups ( P <0.005, Table 1 , Supplementary Figure S3A online) with the exception of EPC compared with CP ( P -0.18). At its optimal cutoff determined by Receiver Operating Characteristic curve analyses (≥ 68.7 U/ml), CA19-9 diff erentiated HC, BC, and CP from unresectable LPC with very-high SNs/SPs of 82%/95%, 77%/89%, and 77%/86%, respectively ( Supplementary ANOVA, analysis of variance; BC, controls with benign diseases; CP, chronic pancreatitis; EPC, early-stage pancreatic cancer, resectable; HC, healthy controls, cancer; LPC, late-stage pancreatic cancer, unresectable; PC, pancreatic cancer; Q1, fi rst quartile; Q3, third quartile. a P -values are from ANOVA models conducted on the log scale and adjusted for multiple comparisons with Tukey's method. As mucins are complex protein and could not be purifi ed to entirety concentration are relative to total cell lysate (ng/ml). 
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Similarly, the performance of CA19-9 for diff erentiating EPC from BC cases signifi cantly improved in combination with MUC5AC (AUC=0.57-0.86; SN/SP=67%/48% to 75/83%, AUC diff erence=0.3). Furthermore, to discriminate EPC from CP, the inclusion of MUC5AC improved the SN/SP of CA19-9 (AUC from 0.5 to 0.83; SN/SP from 67%/33% to 75%/80%; AUC diff erence=0.33; p-value<0.001). Th e combination also diff erentiated controls (i.e., BC and CP) from EPC cases (AUC=0.84; CI: 0.77-0.90; SN/SP of 75% and 83%, respectively; Figure 3c , Table 3 ). Importantly, the combination outperformed both MUC5AC and CA19-9 in diff erentiating PC cases from various benign and CP cases. In case of MUC5AC, the decrease in sensitivity was lower than the enhancement in the specifi city that lead to an overall increase in the AUC from 0.88 to 0.91 suggesting an overall merit in combining the biomarkers ( Table 3 ) .
Next, this study evaluated the diagnostic performance of MUC5AC in all three sets ( n =656; training set and validation sets I and II; Figure 3e-f ) . Overall, in all the three sets, MUC5AC was found to be highly sensitive and specifi c in diff erentiating EPC from BC and CP cases, with AUCs of 0.82 and 0.77 respectively ( Figure 3f and Supplementary Table 2 ).
DISCUSSION
A minimally invasive, early diagnostic test that has high sensitivity and specifi city and is capable of distinguishing PC at resectable stages from benign diseases is highly desirable. Notably, MUC5AC expression is undetectable in the normal pancreas, cancer adjacent normal pancreas, and the chronically infl amed pancreas, but exhibits diff erential expression in cases of PC, thus suggesting its utility as a diagnostic biomarker. While evaluating the utility of MUC5AC as a biomarker for cholangiocarcinoma, Wongkham et al. ( 16 ) observed undetectable levels of MUC5AC in the serum of patients with benign or chronic infl ammation of the bile duct, cholecystitis, cholelithiasis, and opisthorchiasis. In contrast, a study by Albert et al. ( 17 ) showed the marked elevation of serum CA19-9 in patients with cirrhosis and acute cholangitis. Th ese studies support that MUC5AC is a better marker than CA19-9 for diff erentiating malignant and benign hepatobiliary, pathologies. Findings from the present study elaborates strong diagnostic and prognostic potential of MUC5AC which exhibited SN/SP of 75%/73% for diff erentiating controls from PC in validation set 1, at the pre-defi ned cut-off value of 20.4 ng/ml. Th ese control samples were obtained from patients that presented with epigastric pain/discomfort and were subsequently subjected to endoscopic ultrasound guided-fi ne needle aspiration for evaluation; their follow-up ascertained that these patients were free of pancreatic disease ( 14 ) .
Biliary obstruction is one of the major confounding factors for accurate detection of PC. We observed that the SN/SP of MUC5AC increased in samples with low bilirubin levels (≤1.5) compared with those with high bilirubin levels. Th is suggests that the degree of biliary obstruction possibly aff ects circulating MUC5AC levels in cancer patients. Similarly, CA19-9 concentrations have been found to be aff ected by biliary obstruction, where high bilirubin levels aff ect the performance of CA19-9 as prognostic marker. In addition, a study by Dumitra et al. ( 18 ) showed that, in adenocarcinomas at the head of the pancreas, the ratio of CA19-9 to biliru- control groups having FHPC. Amongst the previously described benign controls, elevated levels of MUC5AC were observed in two cases of adenoma (from colon screen controls) and one case of cholangiocarcinoma, which are plotted separately in Supplementary Figure S1D online. As evident from the fi gure, it was diffi cult to attribute elevated levels of MUC5AC (when observed) to a bin provides superior predictive abilities as prognostic biomarker compared withthat of CA 19-9 alone. Th e present study explored levels of MUC5AC in various benign groups [abnormal imaging/benign fi ndings in endoscopic ultrasound; AP, common bile duct (CBD) stones, choledocele, duodenal ulcer] and performed additional analyses of MUC5AC levels in acute pancreatitis and Characteristic (ROC) curves comparing the ability of MUC5AC, CA19-9, and duo combination for differentiating resectable EPC from all controls (i.e., healthy controls, benign, and CP) in the training set. The combined use of MUC5AC with CA19-9 signifi cantly improved the AUC and ability to differentiate various types of controls from resectable EPC controls in comparison to CA19-9 alone. ( d ) ROC curves comparing the ability of MUC5AC and CA19-9 with differentiate PC from all control (healthy controls, benign, and CP). ( e ) ROC curves comparing the ability of MUC5AC with differentiate all PC cases (i.e., EPC and LPC) from all controls (i.e., healthy controls, benign, and CP) in the combined sets (training set, validation set I, and validation set II). ( f ) ROC curves comparing the performance of MUC5AC to differentiate resectable PC from all controls (i.e., healthy controls, benign, and CP) in the combined set (i.e. training set, validation set I, and validation set II; n = 657). The ROC curves in the fi gures are plotted taking MUC5AC, CA19-9 and combination (MUC5AC + CA19-9) as continuous variable and optimal AUC curve were plotted. Overall, MUC5AC emerged as SN/SP marker for differentiating EPC cases from various types of controls. CP, chronic pancreatitis; HC, healthy controls; EPC, early-stage pancreatic cancer; LPC, late-stage pancreatic cancer; SN, sensitive; SP, specifi c.
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MUC5AC and CA19-9 in Early Diagnosis of Pancreatic Cancer specifi c sub-group, either due to variability or to limited sample size. Further, the control group with family history of pancreatic cancer (FHPC) showed that some individuals had visible levels of MUC5AC. However, there is currently no follow-up information available for these subjects to determine if this was an indication of occult malignancy. To accurately access and utilize MUC5AC as a potential biomarker, these observations warrant the future assessment of MUC5AC levels in a longitudinally collected sample sets from patients with initial presentation of benign disease. Th e post-and pre-surgical monitoring of MUC5AC levels in Estimated threshold for MUC5AC+CA19-9 models determined by multivariate model. The difference between multivariate models I and II is that the former used a CA19-9 as continuous variable, whereas the latter used the clinical threshold of 37 U/ml.
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the signifi cance of this novel marker in combination with CA19-9, without economically over burdening the critical patient care. Considering the high diagnostic effi cacy of MUC5AC, it will be of interest to evaluate its performance in pre-diagnostic cohorts. However, due to relatively low incidences and predominantly sporadic nature of PC, such samples are rarely available. Th e best opportunity for obtaining pre-diagnostic samples will be through examining high-risk groups, including individuals with history of hereditary pancreatitis, Peutz-Jeghers disorder, familial atypical multiple mole melanoma, cystic fi brosis, familial cancer syndrome such as Lynch syndrome, familial adenomatous polyposis (APC mutation), and BRCA2 mutations as well as individuals with FHPC. Eff orts are underway in our laboratory to evaluate MUC5AC levels in these high risk cohorts. Further, we plan to validate MUC5AC in a longitudinally collected prostate, lung, colorectal, and ovarian (PLCO) study set in which some patients developed PC.
Finally, considering the high potential of MUC5AC and CA19-9 combinations, we are highly hopeful that present study will pave the way to the development of a biomarker panel that can help achieve overarching challenge of improving the 5 years survival rate from <6 to 20% by pancreatic cancer society in near future. In addition, the MUC5AC based diagnostic test could be of high utility in patients with suspicion of pancreatic adenocarcinoma (pancreatic mass) in imaging, as it is well known that 5-10% of these patients who undergo resective surgery have a fi nal diagnosis of benign disease. Findings from this study strongly support future trials to evaluate the diagnostic/prognostic utility of MUC5AC for atypical/suspicious for malignancy on fi ne-needle aspiration (FNA) of pancreatic mass lesions that account for 2% to 29% in various studies. Overall, the encouraging fi ndings from this study strongly support that future trials assess the diagnostic/prognostic utility of MUC5AC for diagnosing PC.
